These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 6818779)

  • 21. Clinical experience with bezafibrate.
    Schubotz R; Schneider J; Hausmann L; Mühlfellner G; Mühlfellner O; Kaffarnik H
    Artery; 1980; 8(6):553-9. PubMed ID: 7259534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Changes in the fatty acid composition of erythrocyte and platelet membranes after diet therapy in patients with hyperlipoproteinemia type II].
    Korf II; Meshcheriakova VA; Samsonov MA; Chepurnenko NV; Koshechkin VA
    Vopr Med Khim; 1987; 33(3):73-7. PubMed ID: 3630021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
    Vorberg G; Ziegler WJ
    Arzneimittelforschung; 1980; 30(11b):2068-72. PubMed ID: 7194062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
    Altomonte L; Mingrone G; Negrini A; De Cunto F; Greco AV
    Clin Ter; 1981 Jan; 96(1):31-8. PubMed ID: 7016409
    [No Abstract]   [Full Text] [Related]  

  • 25. [The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
    Mertz DP; Loewer H; Suermann I
    Med Klin; 1979 Dec; 74(51-52):1953-6. PubMed ID: 542179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
    Schwartzkopff W; Luley C; Scheffler W; Lehmann-Leo W; Schilling A; Wegscheider K
    Med Welt; 1982 Apr; 33(17):631-7. PubMed ID: 7098826
    [No Abstract]   [Full Text] [Related]  

  • 27. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
    Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
    Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long-term behavior of serum fatty acids--results of a Leipzig gerontologic longitudinal study].
    Reuter W; Sauer I; Seifart C
    Z Gesamte Inn Med; 1984 Aug; 39(16):397-9. PubMed ID: 6506815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fatty acid metabolism in primary hyperlipoproteinemia].
    Reuter W
    Z Gesamte Inn Med; 1979 Oct; 34(20):suppl 287-9. PubMed ID: 398634
    [No Abstract]   [Full Text] [Related]  

  • 31. Metabolism of plasma and biliary lipids in hyperlipoproteinaemia.
    Leijd B
    Acta Med Scand Suppl; 1979; 635():1-32. PubMed ID: 295570
    [No Abstract]   [Full Text] [Related]  

  • 32. [Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia].
    Lageder H
    Wien Klin Wochenschr; 1980 Feb; 92(3):95-101. PubMed ID: 6985560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of a basic metabolic diet rich in polyene fatty acids on the pattern of glycerophospholipid fatty acids in patients with hyperlipoproteinemia].
    Reuter W; Heybey U
    Z Gesamte Inn Med; 1984 Mar; 39(6):100-2. PubMed ID: 6730581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible glucagon-mediated hypocholesterolemic activity of a nicotinic acid derivative (sorbinicate).
    Uccella R; Morenghi R; Agosti C; Saponati G
    Artery; 1983; 11(5):400-12. PubMed ID: 6661043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias].
    Honorato Pérez J; Azanza Perea JR
    Rev Med Univ Navarra; 1982 Mar; 26(1):51-4. PubMed ID: 7111953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Fatty acid composition of triglycerides in inflammatory liver diseases in diabetics with and without hyperlipoproteinemia].
    Singer P; Honigmann G; Schliack V
    Z Gesamte Inn Med; 1981 Aug; 36(15):513-9. PubMed ID: 7293284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Nicotinic acid and derivatives for therapy of hyperlipoproteinemia].
    Ishikawa T
    Nihon Rinsho; 1994 Dec; 52(12):3292-7. PubMed ID: 7853725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Longterm therapy and etofibrate (author's transl)].
    Kaffarnik H; Schneider J; Schubotz R; Zöfel P
    MMW Munch Med Wochenschr; 1980 Jan; 122(3):95-8. PubMed ID: 6767931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P; Weisweiler P
    Artery; 1980; 7(6):464-70. PubMed ID: 7236016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum lipoprotein fatty acid patterns in various types of familiar combined hyperlipidemia.
    Hrebícek J; Chmela Z; Skottová N; Bartek J; Vecera R
    Acta Univ Palacki Olomuc Fac Med; 1995; 139():19-23. PubMed ID: 8686553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.